Group items tagged

Working towards its five-year strategy, the Royal Pharmaceutical Society (RPS) has put some plan in place to change its existing structure at the executive level, which could potentially render some senior positions redundant. Though the process is in nascent stage, "two roles have been identified at potential risk of redundancy," RPS said in a statement on Thursday (March 3) afternoon, adding: "This is very much at proposal stage and no final decisions or outcomes have been reached."0 It didn't specify which two roles were going to be axed, saying: "We are unable to go into the specifics of the process for individuals due to its confidential nature, but we will of course go through a fair, reasonable and confidential consultation process and are supporting the individuals involved. "No one should be in any doubt that our commitment to education and the profession's development remains the highest priority for us, and equally support for our members, thought leadership and advocacy are core to what we do as a professional leadership body."

The result from the Royal Pharmaceutical Society (RPS)'s survey showed that pharmacists witnessed 'the cost of living is having an impact on whether people can afford prescription medicines in England'. RPS has long campaigned to remove prescription charges for people with long-term conditions in England because they create a financial barrier to patients receiving the medicines needed to keep them well. The charge currently stands at £9.35 per item prescrib9ed and an annual rise usually occurs in April. Prescriptions are free for people in Scotland, Wales and Northern Ireland. One in two pharmacists who responded to the survey said they've seen an increase in the last six months in patients asking them which medicines on their prescription they can 'do without' due to affordability issues. One in two pharmacists had seen a rise in people not collecting their prescription, whilst two out of three pharmacists reported an increase in being asked if there was a cheaper, over-the-counter substitute for the medicine they had been prescribed.

The Scottish government has appointed Christina McKelvie MSP as the new Minister for Drugs and Alcohol policy, following the resignation of Elena Whitham MSP due to health reasons. In a letter to the First Minister, Whitham said she was receiving treatment for post-traumatic stress, which had "greatly" affected her wellbeing. Commenting on the news, Royal Pharmaceutical Society (RPS) Scotland thanked Whitham for supporting them, particularly for her "efforts to bring in a new national service to provide emergency access to supplies of naloxone." RPS Scotland has continuously advocated for the accessibility of naloxone through all community pharmacies (for supply to people who use drugs, family, healthcare professionals and carers), and to make it available in all clinical settings for use in emergencies. It was also the top recommendation of their policy on Pharmacy's role in reducing harm and preventing drug deaths.

Professor Ryan Donnelly, esteemed for his groundbreaking contributions to pharmaceutical science, has been awarded the prestigious Royal Pharmaceutical Society (RPS) Harrison Memorial Medal for 2024. This distinguished accolade, presented in honour of the renowned pharmaceutical chemist Col EF Harrison, serves as a testament to Professor Donnelly's exceptional achievements. Currently holding the position of Chair in Pharmaceutical Technology at Queen's University Belfast's School of Pharmacy and Director of Research, Professor Donnelly has garnered acclaim for his pioneering work in developing advanced polymeric drug delivery systems. Specialising in transdermal and intradermal drug delivery methodologies, his research aims at optimising patient outcomes through innovative pharmaceutical technologies.

A three-year contract has been signed between NHS Education for Scotland (NES) and Pharmaceutical Press, the Royal Pharmaceutical Society's (RPS) knowledge business, to continue the supply of trusted medicines information though MedicinesComplete, to healthcare professionals in Scotland. The renewed investment from NES demonstrates unequivocal confidence in the publisher and highlights Pharmaceutical Press' ongoing commitment to provide practical and evidence-based guidance, supporting those who prescribe, dispense, and administer medicines. Essential resources include Martindale: The Complete Drug Reference, Palliative Care formulary, Stockley's Drug Interactions and Critical Illness. Relied on by healthcare professionals globally for use in everyday practice, clear and concise guidance through MedicinesComplete supports confident decision-making at the point of care.

The Royal Pharmaceutical Society (RPS) has said that it strongly supports the UK government's proposal that individuals born on or after 1 January 2009 should be prohibited from legally purchasing tobacco products. It has also shown its agreement to several other actions proposed by the Department of Health and Social Care's (DHSC) for 'Creating a Smokefree Generation and Tackling Youth Vaping' including: The inclusion of all tobacco products, cigarette papers, and herbal smoking products in the new legislation. Restrictions on the sale and supply of disposable vapes, and vape flavours. RPS President, Professor Claire Anderson, said: "Our recommendations reflect a commitment to creating a future free from the harms of tobacco and youth vaping. It's crucial to prohibit access for the youngest generation, regulate all tobacco-related items, and address the allure of flavoured e-cigarettes."

Representatives for prescribers across Scotland, politicians, academics and clinicians gathered to discuss the importance of environmental sustainability in healthcare during a Scottish Parliamentary reception held at Holyrood on Wednesday (13 December). Royal Pharmaceutical Society (RPS) informed the parliament that medicines account for around 25 per cent of carbon emissions across the NHS, while highlighting the various innovative ways to reduce these carbon emissions. The NHS in Scotland needs to implement effective environmentally sustainable approaches to healthcare in order to meet its ambition to achieve net zero, RPS pointed out. Laura Wilson, Director for Scotland at RPS, said: "It was fantastic to bring together pharmacists, parliamentarians and partners from across government and healthcare to highlight the huge opportunity which exists in healthcare to make our systems and processes more environmentally sustainable.

Recognising the changing practices in healthcare, the Royal Pharmaceutical Society (RPS) has revised and updated its position on the separation of prescribing and dispensing or administration of a medicine by the same healthcare professional. It's previous guidance, published in March 2020, restricted prescribing and dispensing by the same healthcare professional only in exceptional circumstances. The new guidance, jointly developed with the Royal College of Nursing (RCN), has made prescribing and dispensing of medicines more flexible. It clarifies that "where there is a risk assessment in place and in the best interests of the patient, the same healthcare professional can be responsible for the prescribing and dispensing / supply / administration of medicines." The change in the position statement follows an extensive year-long engagement exercise with medical associations, members, fellows, expert advisory groups, patient groups and the RPS Country Boards.

Even as the UK agrees deals for 14 million additional vaccine doses from Moderna and Pfizer, the Royal Pharmaceutical Society has renewed its calls for community pharmacies in England to play an increased role in delivering booster jabs for Covid-19. "Pharmacists and pharmacy teams across the health service in England have been crucial to the success of the flu and Covids-19 vaccination programmes from the outset," said Thorrun Govind, chair of the RPS in England, who has been making a case on national television for an increased role of the profession. She added: "They continue to go above and beyond to support patient care, engaging with local communities and helping to overcome vaccine hesitancy. "They've already done so much this year to look after patients in really difficult circumstances, but many will be ready to rise to the challenge of this new national effort."

The country as a whole is facing uncertain and challenging times, and for our profession emerging from the second year of the pandemic, the pressures and stresses don't look to be easing up. It is undeniable that the wellbeing of those in our pharmacy family has suffered and many face emotional and psychological challenges in addition to immense workplace pressure. What do we know about the state of wellbeing within the profession? As the profession's independent charity, it is crucial that Pharmacist Support keeps abreast of the changing needs of the profession to enable us to meet the needs of those we are here to help. To do this, each year we collaborate with the Royal Pharmaceutical Society (RPS) to carry out an annual Workforce Wellbeing Survey. The last survey carried out was in the latter part of 2021 but nothing has changed since. And the results provided stark reading. Of the 1,014 responses received, many reported living with 'poor' or 'very poor' mental health and wellbeing. The survey results highlight a continued clear need for mental health and wellbeing support. Within the survey, it was identified that there is a very clear need for independent assistance, with many saying they feel unable to talk to their employers about their mental health issues. The need for our charity has never been clearer.

In a unified effort to improve women's healthcare, four leading organisations-the Company Chemists' Association (CCA), the National Pharmacy Association (NPA), the Royal Pharmaceutical Society (RPS), and the Faculty of Sexual and Reproductive Healthcare (FSRH)-are calling for the commissioning of a National Emergency Hormonal Contraception (EHC) service in England. They are proposing that this service be provided free of charge through community pharmacies to women of all ages across the country. They emphasised that such a service would "not only transform access to care for all women, but directly tackle health inequalities and vastly improve health outcomes."

Cervical screening is one of the best ways to protect women from cervical cancer, which claims nearly two lives daily in England, according to NHS England. Therefore, all women and those with a cervix between the ages of 25 and 64 are encouraged to attend cervical screening when invited. Sadly, 3 in 10 of those eligible for cervical screening do not take up the potentially life-saving offer, as revealed by the NHS Cervical Screening Programme, England 2022-2023 annual report. Pharmacist Thorrun Govind, also a Healthcare Lawyer (Brabners LLP), underscores the significant role pharmacists and pharmacy teams can play in promoting cervical cancer screening. The former Chair of the Royal Pharmaceutical Society (RPS) in England told Pharmacy Business: "Pharmacists and pharmacy teams are a trusted part of the local community. They therefore have a key part in promoting cervical cancer screening."

The Royal Pharmaceutical Society (RPS) has introduced a new comprehensive learning programme to support pharmacists in Wales to deliver the Pharmacy Independent Prescribing Service (PIPS). Developed in collaboration with Health Education and Improvement Wales (HEIW), the programme is designed to "equip pharmacists with the essential knowledge, skills, and confidence needed to provide excellent patient care." While the primary emphasis is on pharmacists operating within primary care settings, those from various practice settings are also encouraged to register and participate in the programme. Commenting on the collaboration with HEIW, Elen Jones, director for Wales at the Royal Pharmaceutical Society, said that it will empower pharmacists across the country to deliver high-quality prescribing services to local communities.

The Welsh chapter of the Royal Pharmaceutical Society, along with ten other royal colleges and professional bodies, have renewed calls for the urgent transformation of mental health services to address increasing demands on the NHS in Wales. Representatives of the Royal College Mental Health Expert Advisory Group joined members of the Senedd in Cardiff to outline the work of the group over the past year and to explain why a well-trained, fully supported and equipped multi-disciplinary workforce is critical for the development of care for people with mental health conditions. To make sustainable change happen, the group is calling for a greater focus by the Welsh government and NHS Wales on the following: The critical changes needed to improve the delivery and structure of mental health services across Wales in community, hospital and specialist secure settings. Parity of access to mental health services for the most vulnerable patients, ensuring they have equal access opportunities that vulnerable patients would receive for physical health conditions.

The Royal Pharmaceutical Society (RPS) has confirmed that the recall of blood pressure drugs amlodipine and olmesartan by the Food and Drug Administration is only for the US market and will not have any impact in the UK. MHRA also clarified that the manufacturer of these drugs, Macleod Pharmaceuticals, does not supply amlodipine medicines in the UK. It was published online in both the Daily Record and Daily Express on the morning of Monday, March 21, that the drugs had been recalled in the US by the FDA due to deviations from standard manufacturing protocols by the manufacturer. RPS intervened to ensure the articles were edited to make clear that this is not an issue in the UK after confirmation from the MHRA. Amlodipine tablets from Macleod Pharmaceuticals aren't available for wholesale distribution in the UK.

The Health Education England (HEE) has allocated £440,000 to help upskill pharmacists working in adult critical care across England. UK Clinical Pharmacy Association (UKCPA) has confirmed with HEE that UKCPA critical care courses meet the criteria for this funding, for courses that complete before 31 March 2023. "The funding is expected to exceed demand and so it is likely that bids for these UKCPA courses will be approved by HEE, as they meet the learning outcomes in the new RPS/UKCPA/FICM specialist critical care curricula (in development)," said UKCPA.

The Medicine and Healthcare Product Regulatory Agency (MHRA) has recalled all pholcodine-containing medicines from the UK pharmacy due to concerns of its potential to cause a severe allergic reaction in some people having general anaesthesia for surgery. The decision was made following the conclusion of a review of post-marketing safety data by the MHRA. The Commission on Human Medicines (CHM) has considered the evidence of an increased risk of the very rare event of anaphylaxis when exposed to neuromuscular blocking agents (NMBA) and advised that pholcodine-containing medicines should be withdrawn. MHRA has advised pharmacists to consider recommending appropriate treatment alternatives for patients who present with a new dry cough or who are currently taking pholcodine. Royal Pharmaceutical Society (RPS) President Professor Claire Anderson said: "If you are taking a cough medicine (including tablets and syrups), check the packaging, label or Patient Information Leaflet to see if pholcodine is a listed ingredient - if it is, and you have any questions, you can talk to your pharmacist who can suggest a different medicine suitable for you.

The Royal Pharmaceutical Society (RPS) has said that multi-buy deals on paracetamol violate the existing voluntary sales guidelines. The professional body is urging the government to pass legislation that prohibits retailers from making such offers on medicines for pain relief. They have also sent letters to MP Maria Caulfield who is the Minister for Mental Health and Women's Health. The Medicines and Healthcare Products Regulatory Agency (MHRA) is requesting to take action on the legislation at the earliest. The concern raised is that multi-buy offers such as 'buy one get one free' can encourage people to buy and store excess packs, which may lead to accidental or impulsive overdose.

Pharmaceutical Press, the Royal Pharmaceutical Society publishing arm, has announced its partnership with Datapharm Ltd. Under the new partnership, Electronic Medicines Compendium (emc) the latest product to be added to MedicinesComplete, the online medicines information platform from Pharmaceutical Press. MedicinesComplete users can easily search emc information, with direct links to the trusted, clinical guidance from the British National Formulary (BNF). "emc through MedicinesComplete will include printable, ready-to-use patient information leaflets written by manufacturers to use at the point of care, and users will have access to an unlimited number of searches. In addition, emc will also include the full Summary of Product Characteristics (SmPC) document, which accompanies all regulator approved medicines in the UK," said the RPS. Available to all countries outside the UK, emc will be launched early next year on subscription through MedicinesComplete. UK access is available on request.

NHS Greater Glasgow and Clyde has appointed Jennifer Laskey as Scotland's first consultant pharmacist, marking a significant step forward for pharmacy profession in the country. Laskey's new role involves providing support to the West of Scotland Cancer Network, where she will play a pivotal role in enhancing healthcare outcomes. Her appointment underscores the commitment of NHS Greater Glasgow and Clyde to improving patient care and highlights the growing importance of pharmacist-led initiatives in Scotland's healthcare landscape. Laskey, a pharmacist from Scotland, will extend her expertise to bolster the West of Scotland Cancer Network, aiming to enhance outcomes and survival rates across various healthcare settings. As part of recruitment to become a consultant pharmacist, Laskey obtained credentials from the RPS serving in an accredited consultant post ensuring standardisation across the UK for patients and the system.